Prospects for combining immune checkpoint blockade with PARP inhibition

The immunogenicity of a cancer cell is derived from accumulated somatic mutations. However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble. This impaired anti-cancer immunity could be attributed to multiple factors including loss of immunodominant epitope...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Anping, Yi, Ming, Qin, Shuang, Chu, Qian, Luo, Suxia, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744711/
https://www.ncbi.nlm.nih.gov/pubmed/31521196
http://dx.doi.org/10.1186/s13045-019-0784-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744711/
https://www.ncbi.nlm.nih.gov/pubmed/31521196
http://dx.doi.org/10.1186/s13045-019-0784-8

Ejemplares similares